Abstract A054: Comparative efficacy analysis of the polyisoprenylated cysteinyl amide inhibitor and sotorasib in lung cancer NCI-H23 mutant cell models
Abstract
Lung Cancer remains the leading cause of cancer-related deaths worldwide, with African Americans experiencing the highest incidence and mortality rates compared to other ancestry-related groups in the United States. KRAS mutations account for approximately 30% of all cases. While KRASG12C inhibitor Sotorasib shows efficacy, its long-term benefit is limited by compensatory resistance mechanisms such as the overexpression of wild-type KRAS. In addition to resistance, other undrugged KRAS mutants create an urgent need for pan-KRAS therapies with activity across multiple KRAS-mutant subtypes. Polyisoprenylated Amide Cysteinyl Inhibitors (PCAIs) are mutant-agnostic agents that suppress the polyisoprenylation-dependent interactions of monomeric small G-proteins such as KRAS and RHO family GTPases, disrupting downstream signaling. PCAIs NSL-YHJ-2-27 inhibited the viability of NCI-H23 cells with KRASG12C and KRASG12A mutations with EC50 values of 3.0 and 3.2 µM, respectively, while Sotorasib exhibited EC50 values of 15 µM and 24 µM, respectively, against the same cells. At 3 µM, NSL-YHJ-2-27 significantly inhibited colony formation in KRASG12C and KRASG12A by 99 and 72%, respectively. As expected, Sotorasib significantly inhibited colony formation in KRASG12C by 70% but only 36% in KRASG12A cells. NSL-YHJ-2-27 at 5 µM significantly inhibited KRASG12C and KRASG12A cell migration by 64% and 53%, respectively. Sotorasib did not affect KRASG12A cell migration. Transcriptomic RNA sequencing after exposure to 3 µM NSL-YHJ-2-27 revealed the differential expression of genes involved in inflammatory responses, cytoskeletal organization, and apoptotic signaling. Prolonged treatment with 5 µM resulted in the loss of Sotorasib efficacy against KRASG12C cells and no inhibitory effect on KRASG12A proliferation. In contrast, 5 µM NSL-YHJ-2-27 maintained a robust antiproliferative activity, reducing cell counts by 4-fold in both KRASG12C and KRASG12A cells. Collectively, these findings support PCAIs as pan-KRAS therapeutic agents with the potential to overcome the limitations of mutation-specific KRAS drugs. Chase Lilly, Chunli Yan, Matthew Gladstone, Benjamin Ryder, Kyle Phillips, Jahnissi Odoom, Karla Gonzalez, Joshua Kofi Ablordeppey, Ite A. Offringa, Nazarius S. Lamango, Kweku Ofosu-Asante, Desmond Kwakye, Yong Huang. Comparative efficacy analysis of the polyisoprenylated cysteinyl amide inhibitor and sotorasib in lung cancer NCI-H23 mutant cell models [abstract]. In: Proceedings of the 19th AACR Conference on the Science of Cancer Health Disparities; 2026 Oct 18-21; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2026;35(10 Suppl):Abstract nr A054.